摘要
目的观察含肺泰胶囊抗结核治疗方案治疗复治肺结核的临床疗效。方法将113例复治肺结核患者按随机数字表法分为治疗组(58例)和对照组(55例)。两组均采用常规抗结核化疗(治疗方案为3H-R-Z-E/6H-R-E),治疗组加服肺泰胶囊2.5 g,每日3次。两组疗程均为9个月。观察两组患者治疗2、5、8个月末的痰菌阴转率,治疗3、6、9个月末的病灶吸收率及空洞闭合率,治疗1个月末的临床症状缓解率和治疗9个月末不良反应的发生情况。结果治疗2、5、8个月末,治疗组痰菌阴转率分别为[75.00%(21/28)、92.86%(26/28)、96.43%(27/28)]明显高于对照组[41.67%(10/24)、70.83%(17/24)、75.00%(18/24),χ~2=5.96、4.92、5.09,P<0.05]。治疗3、6、9个月末,治疗组病灶吸收总有效率分别为[81.03%(47/58)、94.83%(55/58)、98.28%(57/58)]高于对照组[43.64%(24/55)、61.82%(34/55)、70.91%(39/55),χ~2=16.91、18.39、16.54,P<0.01],且治疗组空洞缩小总有效率分别为[70.00%(28/40)、87.50%(35/40)、95.0%(38/40)]亦优于对照组[27.03%(10/37)、48.65%(18/37)、70.27%(26/37),χ~2=14.20、13.52、8.38,P<0.01]。治疗1个月末,治疗组咳嗽、咳痰、咯血、发热、乏力、盗汗、纳差症状的缓解率均高于对照组(χ~2=4.78、5.59、5.40、4.65、4.25、4.79、4.50,P<0.05)。治疗组药物不良反应发生率为24.13%(14/58),对照组为29.09%(16/55),两组比较,差异无统计学意义(χ~2=0.36,P>0.05)。结论肺泰胶囊与抗结核化疗药物联用治疗复治肺结核,能促进病灶吸收及空洞闭合,加快痰菌转阴。
Objective To observe the clinical efficacy of anti-tuberculosis therapeutic regimen with Feitai Capsule （FC） in the treatment of retreated pulmonary tuberculosis （TB）. Methods Totally 113 retreated TB patients were assigned to the treatment group （58 cases） and the control group （55 cases） by random digit table. All patients received routine anti-tuberculosis chemotherapy （3H-R-Z-E/6H-R- E）. Those in the treatment group took FC 2.5 g each time, 3 times per day. The therapeutic course for all was 9 months. Sputum negative conversation rates after 2,5,8 months, foci absorption and void closure rates after 3, 6, 9 months, clinical symptoms remission rates after 1 month, and incidence of adverse reactions after 9 months were detected. Results After 2, 5, 8 months of treatment, the sputum nega- tive conversion rates were 75.00% （21/28）, 92.86% （26/28）, 96.43% （27/28） in the treatment group, obviously higher than those of the control group E41.67% （10/24）, 70.83% （17/24）, 75.00% （18/24）, χ2 =5.96, 4.92,5.09, P 〈0.05]. After 3, 6, 9 months of treatment, the total foci absorption rates were 81.03%（47/58）, 94.83%（55/58）, 98.28%（57/58） in the treatment group, significantly higher than those of the control group [43.64% （24/55）, 61.82% （34/55）, 70.91% （39/55） ], χ2 =16.91, 18.39, 16.54, all P 〈0.01 ~. And the total void closure rates were [70.00% （28/40）, 87.50% （35/40）, 95.0% （38/40） 3 in the treatment group, significantly higher than those of the control group E27.03% （10/37）, 48.65%（18/37）, 70.27% （26/37）, χ2 =14.20, 13.52, 8.38, P 〈0.01 ]. The remission rates of cough, expectoration, hemoptysis, fever, fatigue, night sweat and anorexia in the treatment group were all higher than those of the control group （χ2 =4.78,5.59,5.40,4.65,4.25,4.79,4.50, P 〈0.05） after 1 month of treatment. The incidence of adverse reactions in the treatment group was 24.13 % （14/58）, and 29.09% （16/55） in the control group,with no
出处
《中国中西医结合杂志》
CAS
CSCD
北大核心
2017年第10期1196-1200,共5页
Chinese Journal of Integrated Traditional and Western Medicine
关键词
肺泰胶囊
抗结核治疗
复治肺结核
临床疗效
Feitai Capsule
anti-tuberculosis therapy
retreated pulmonary tuberculosis
clinical effects
